A New Resource Provides a Sanctuary for Black TNBC Patients
The Black TNBC Sanctuary is a resource that provides key information and resources specifically for Black patients with TNBC.
Progress Against Cancer
The Black TNBC Sanctuary is a resource that provides key information and resources specifically for Black patients with TNBC.
HPV vaccine credited for decrease in cervical cancer deaths among young women, and new technology extends survival in locally advanced pancreatic cancer.
The FDA approved durvalumab for some patients with previously treated limited-stage small cell lung cancer. The U.S. Food and Drug Administration (FDA) has approved durvalumab (Imfinzi) for the treatment of adults with limited-stage...
The FDA approved the targeted therapy zenocutuzumab-zbco for certain patients with lung or pancreatic cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zenocutuzumab-zbco (Bizengri) for the treatment of adult...
As we head into the holiday season, Cancer Research Catalyst has tantalizing teasers in the form of science stocking stuffers straight from our November edition of Editors’ Picks. This month, the editors of the...
Pancreatic cancer surge in younger people has not led to a rise in deaths, and researchers will study long-term survivors to better understand cancer responses.
The FDA granted accelerated approval to the first-in-class HER2-directed bispecific antibody zanidatamab-hrii. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zanidatamab-hrii (Ziihera) for previously treated, unresectable or metastatic human epidermal...
The FDA Project Renewal initiative has updated the approved indications for fludarabine phosphate chemotherapy in chronic lymphocytic leukemia. The U.S. Food and Drug Administration (FDA) has approved updated labeling of fludarabine phosphate (Fludarabine Phosphate...
Using high-dose testosterone after prostate cancer stops responding to androgen deprivation therapy can stop tumor growth.
The FDA approved revumenib, a first-in-class menin inhibitor, to treat acute leukemias with a KMT2A translocation. The U.S. Food and Drug Administration (FDA) has approved revumenib (Revuforj) for the treatment of adult and pediatric...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More